Management of ATT-Induced Hepatotoxicity

Current Clinical Assessment

The British Thoracic Society recommends continuing ATT with close monitoring and repeat liver function tests weekly in asymptomatic patients with AST elevation to 160 U/L, which is approximately 3-4 times normal, as this does not yet meet the threshold for stopping treatment 1
The patient presents with AST 160 U/L, approximately 3-4 times the upper limit of normal, and ALT 63 U/L, approximately 1.5 times the upper limit of normal, with total bilirubin 0.6 mg/dL being normal 1, 2
The patient has no symptoms, such as fever, malaise, vomiting, jaundice, or abdominal pain, and has high-risk features including elderly age, female gender, diabetes, CKD, and poor nutritional status 1, 2

The threshold for stopping rifampicin, isoniazid, and pyrazinamide is AST/ALT ≥5 times normal or any bilirubin elevation, which has not been reached in this patient 1, 2
The British Thoracic Society guidelines state that if AST/ALT is 2-5 times normal, treatment should be continued with weekly monitoring for two weeks, then biweekly until normal 1

Repeat liver function tests should be done weekly until values normalize or reach the threshold for stopping (AST/ALT ≥5× normal) 1, 2
The patient should be monitored for symptoms at each visit, and educated to stop medications immediately and report if any symptoms develop 1, 2

CKD management is critical, and renal function should be verified before continuing ethambutol, with dose adjustment as necessary 1, 3
Patients with diabetes should be checked for gastroparesis, which may affect drug absorption 3
Consider checking for viral hepatitis coinfection in high-risk patients 1

If hepatotoxicity worsens, discontinue rifampicin, isoniazid, and pyrazinamide immediately, and consider switching to streptomycin and ethambutol, with careful dose adjustment and serum drug concentration monitoring in patients with CKD 1, 2, 3
Alternative treatments, such as fluoroquinolones (levofloxacin or moxifloxacin) plus ethambutol, may be considered if streptomycin is contraindicated by renal function 3

Drugs should be reintroduced sequentially with daily clinical and biochemical monitoring, starting with isoniazid, then rifampicin, and finally pyrazinamide, with gradual dose increases as tolerated 1, 2
Monitor liver function daily during reintroduction, and be cautious of recurrent hepatotoxicity, particularly with pyrazinamide 1, 2

Do not stop treatment prematurely at current enzyme levels in an asymptomatic patient with active TB, as this risks treatment failure and drug resistance 1
Do not ignore bilirubin elevation, as any rise in bilirubin mandates immediate cessation of hepatotoxic drugs regardless of transaminase levels 1, 2
Do not use streptomycin without dose adjustment in CKD, and require therapeutic drug monitoring 1, 3
Do not assume all enzyme elevations are drug-induced, as TB itself can cause hepatic dysfunction 3